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ABSTRACT: Transfers of carbene moieties to heterocycles or cyclic alkenes to obtain C(sp2)‒H alkylation or cyclopropane products 
are valuable transformations for synthesis of pharmacophores and chemical building blocks. Through their readily tunable active site 
geometries, hemoprotein “carbene transferases” could provide an alternative to traditional transition metal catalysts by enabling 
heterocycle functionalizations with high chemo-, regio- and stereocontrol. However, carbene transferases accepting heterocyclic 
substrates are scarce; the few enzymes capable of heterocycle or cyclic internal alkene functionalization described to date are 
characterized by low turnovers or depend on artificially introduced, costly iridium–porphyrin cofactors. We addressed this challenge 
by evolving a cytochrome P450 for highly efficient carbene transfer to indoles, pyrroles, and cyclic alkenes. We first developed a 
spectrophotometric high-throughput screening assay based on 1-methylindole C3-alkylation that enabled rapid analysis of thousands 
of P450 variants and comprehensive directed evolution via random and targeted mutagenesis. This effort yielded a P450 variant with 
11 amino acid substitutions and a large deletion of the non-catalytic P450 reductase domain, which chemoselectively C3-alkylates 
indoles with up to 470 turnovers per minute and 18,000 total turnovers. We subsequently used this optimized alkylation variant for 
parallel evolution towards more challenging heterocycle carbene functionalizations, including C2/C3 regioselective pyrrole alkylation, 
enantioselective indole alkylation with ethyl-2-diazopropanoate, and cyclic internal alkene cyclopropanation. The resulting set of 
efficient biocatalysts showcases the tunability of hemoproteins for highly selective functionalization of cyclic targets and the power 
of directed evolution to enhance the scope of new-to-nature enzyme catalysts. 
Introduction 
Cyclic compounds, particularly heterocycles, are key compo-
nents in biologically active compounds, from the building 
blocks of life (e.g. nucleic acids, amino acids and carbohy-
drates) to natural products with pharmacologically relevant ac-
tivities (e.g. vitamins, alkaloids and antibiotics). Accordingly, 
heterocycles have been playing an increasingly significant role 
in the modern repertoire of medicinal chemistry,1 with mole-
cules containing at least one heterocyclic fragment comprising 
nearly 60 % of FDA-approved pharmaceuticals.2 Because het-
erocycles are powerful handles to regulate polarity, lipophilicity 
and hydrogen bonding properties, extensive efforts are directed 
at tuning these structures to manipulate the pharmacological, 
pharmacokinetic and toxicological features of drug candi-
dates.3–5 Therefore, development of selective and efficient 
methods for functionalization of heterocycles will streamline 
synthesis of medicinal compounds and pharmacophores. 
One major way to derivatize heterocyclic fragments is to di-
rectly functionalize C‒H bonds with new chemical entities.6 Al-
ternatively, one can derivatize ring structures by functionalizing 
existing C‒C bonds7. Nature employs different enzymatic ma-
chineries to accomplish these two processes. For instance, me-
thyltransferases install methyl moieties on the C‒H bonds of 
DNA bases;8 flavin-dependent halogenases are responsible for 
installing halogens on heterocycle-based natural products, such 
as indoles, pyrroles and azoles;9 and (mono)oxygenases like cy-
tochrome P450s or flavoenzymes are involved in oxidation of 
heterocyclic substrates to induce or lose aromaticity.10–12 
To expand nature’s capacity for functionalization of (hetero)cy-
clic molecules, we wished to use recently developed “carbene 
transferase” enzymes to functionalize carbon‒hydrogen and 
carbon‒carbon double bonds in heterocycles. Carbene transfer-
ases are engineered heme-dependent proteins capable of trans-
ferring carbene moieties to different target compounds.13 Reac-
tivities developed in recent years include carbene transfer to 
olefins,14–16 alkynes,17 and X‒H bonds (X = C, N, S, Si, B)18–23 
to generate chemical structures often not found in nature. These 
enzymatic transformations grant biocatalytic access to im-
portant pharmaceuticals including levomilnacipran, ticagrelor, 
tasimelteon, tranylcypromine and others.24–26 
However, enzymatic carbene transfer for heterocycle derivati-
zation faces several challenges. Carbene transfer has been 
achieved mostly for sterically unhindered functional groups, 
such as terminal olefins. Thus it remains to be determined 
whether sterically more demanding, internal carbon‒carbon 
double bonds in heterocycles can be efficiently functionalized. 
A second challenge for enzymatic carbene transfer to heterocy-
cles is selectivity. Synthetic chemists have used transition metal 
catalysts based on Rh, Ru, Pd, Cu and others to selectively 
transfer carbenes to heteroarenes, such as indoles and pyrroles, 
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 yielding either cyclopropanes or C(sp2)‒H alkylation prod-
ucts.27–32 Mimicking this activity would require enzymes to 
have exquisite control over chemo-, regio- and stereo-selectiv-
ity. Here, we set out to direct the evolution of enzyme catalysts 
with high activity and selectivity in heterocycle carbene func-
tionalization reactions. 
Towards this goal, we used a two-stage engineering approach. 
We first evolved a cytochrome P450 variant for C3 alkylation 
of indoles, using a high-throughput spectrophotometric screen 
that allowed us to evaluate several thousand enzyme variants 
per generation. This enabled a mutagenesis strategy targeting 
the entire P450 protein sequence, which delivered a variant con-
taining 11 mutations as well as a truncation of a large part of the 
non-catalytic reductase domain and which chemoselectively 
and efficiently alkylates indoles. Hypothesizing that this en-
zyme, evolved for alkylation of a heterocyclic substrate, would 
provide a launch pad for further exploration of challenging het-
erocycle functionalizations, in the second stage we performed 
parallel directed evolution to engineer a set of P450 catalysts 
capable of regio-divergent pyrrole alkylations, enantioselective 
indole alkylations with α-disubstituted carbenes, and stereose-
lective cyclic alkene cyclopropanations. 
 
Results and Discussion 
Leveraging a high-throughput screening assay to evolve a 
cytochrome P450 for indole alkylation 
We began by testing a range of hemoproteins for carbene trans-
fer (using ethyl diazoacetate (EDA) as carbene precursor) to a 
selection of heterocyclic substrates (Supplementary Table 1). 
Cytochrome P450-BM3 variant P411-CIS, a serine-ligated var-
iant previously evolved for styrene cyclopropanation,14 stood 
out as highly active for C3-alkylation of 1-methylindole, cata-
lyzing this reaction with 14% yield and 690 TTN. To our de-
light, we found that the resulting alkylated product 3a showed 
a pronounced red-shift in UV absorbance compared to 1-me-
thylindole. This difference in absorbance properties allowed us 
to develop a simple UV-Vis spectrophotometric screening as-
say, in which the catalytic activities of enzyme variants for the 
alkylation reaction (performed in whole Escherichia coli (E. 
coli) cells) could be measured by UV absorbance at 305 nm in 
a 96-well plate reader (Figure 1A, Supplementary Figure 1). 
P411-CIS is a 1048-residue protein consisting of a heme do-
main containing the active site (residues 1-470) and a reductase 
domain that shuttles electrons from NADPH to the heme do-
main and is essential for P450-BM3’s native oxo-transfer chem-
istry (residues 471-1048, subdivided into FMN and FAD do-
mains; Figure 1B).35 Having a screen that enables analysis of 
several thousand enzyme variants, we introduced mutations 
throughout the heme and reductase domains using both random 
mutagenesis and site-saturation mutagenesis and screened the 
resulting libraries for improved 1-methylindole alkylation ac-
tivity (Supplementary Table 2).  
After six rounds of directed evolution for formation of 3a, of 
which the last four rounds were conducted under aerobic con-
ditions, we obtained a P411 variant we refer to as P411-HF 
(Heterocycle Functionalization) (Figure 1C). This variant con-
tains eight mutations in the heme domain, three in the FMN do-
main and a stop codon at the end of the FMN domain (Q674*), 
which deletes the entire FAD domain (Figure 1B, Supplemen-
tary Figure 2). Of these mutations, five were introduced by site-
saturation mutagenesis (V87T, H92F, L181G, I263M, T438C),  
 
Figure 1: Evolution of P411-CIS for 1-methylindole C3 
alkylation. (A) Screening reaction used to evolve P411 variants for 
higher indole alkylation activity. (B) Domain structure of P450-
BM3. As a crystal structure of the entire P450-BM3 protein is 
lacking, individual domain structures with approximate domain 
boundaries are shown (pdb entries: heme domain 4h2314; FMN 
domain 1bvy33; FAD domain 4dqk34); co-factors are shown in red. 
(C) Evolutionary lineage from P411-CIS to P411-HF T327P 
A328S. Data were obtained from two independent assays with six 
replicates per variant, run in 96-well plates under aerobic 
conditions with 10 mM 1 and 15 mM 2 at room temperature (RT) 
for 16h. 
and seven (N201S, L215Q, V281L, K472T, N573D, F646S, 
Q674*) were introduced by random mutagenesis. A final round 
of double site-saturation mutagenesis library screening on 
P411-HF revealed mutations T327P and A328S. This enzyme 
delivered the alkylated product with up to 2700 TTN in aerobic 
96-well plate screening reactions (Figure 1C). 
 
P411-HF: A catalyst for chemoselective alkylation of unpro-
tected indoles 
P411-HF is a highly active alkylation enzyme: analytical 
whole-cell reactions with P411-HF under anaerobic conditions 
with 30 mM 1-methylindole and 1.5 equivalents of EDA deliv-
ered alkylation product 3a in 95% yield with almost 12,000 
TTN (Figure 2A, entry 2). Under catalyst-limiting conditions, 
P411-HF delivered more than 18,000 TTN (Figure 2A, entry 4). 
Under aerobic conditions, variant P411-HF T327P A328S 
proved superior to P411-HF and delivered the alkylated product 
in 74% yield and with 1670 TTN (Figure 2A, entry 6; P411-HF 
delivered 3a in 46% yield under these conditions). Thus, even 
with four rounds of directed evolution under aerobic conditions, 
Page 2 of 9
ACS Paragon Plus Environment
Journal of the American Chemical Society
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 P411-HF is about an order of magnitude more effective under 
anaerobic conditions. Furthermore, P411-HF delivers almost 
two orders of magnitude higher TTN than recently reported var-
iants of the hemoproteins Mb or YfeX catalyzing indole alkyl-
ations (170 to 240 TTN),36,37 and up to three orders of magni-
tude higher TTN than Rh, Cu, Pd or Fe-based transition metal 
catalysts reported for the same type of reaction.30,31,38–40 
To investigate catalyst lifetime, we tested sequential additions 
of 10 mM 1 and 2 substrate equivalents to whole-cell reactions 
in 30-min intervals. This did not increase product formation, 
which indicates that the enzyme is inactivated during the reac-
tion (Supplementary Figure 3A). Furthermore, a 10-minute 
EDA pre-incubation of P411-HF whole-cell catalyst resulted in 
a 26% loss in catalytic activity (Supplementary Figure 3B). Pre-
sumably, alkylation of enzyme residues and/or the porphyrin 
cofactor limits enzyme lifetime, which may possibly be ad-
dressed by further directed evolution.41 
P411-HF anaerobic whole-cell reactions reached completion af-
ter 2 h. The high initial turnover frequency (TOF) of 470 turn-
overs min-1 represents a 35-fold increase over the parent variant 
P411-CIS (Figure 2B). Under aerobic conditions, P411-HF 
T327P A328S showed an initial rate of 21 turnovers min-1, com-
pared to 3 turnovers min-1 for P411-CIS (Figure 2C). The initial 
rates of P411-HF compare well to previously disclosed Mb var-
iants, which exhibited ~10 turnovers min-1 in the alkylation of 
indole with EDA under anaerobic conditions.36 
The most striking mutation found during the directed evolution 
was the truncation of the FAD domain; introduction of the stop 
codon by Q674* reduces the size of the protein catalyst by 35% 
(from 1048 to 673 residues) and increases reaction yield by ca. 
1.7-fold, driven primarily by an increase in protein expression 
level (ca. 1.6-fold) with a slight increase in TTN (Figure 1B, 
Supplementary Figure 4A). Comparable positive effects of de-
leting the FAD domain have subsequently been observed for 
other P411-catalyzed carbene transfer reactions: FAD trunca-
tion discovered in the course of this study proved beneficial for 
carbene C(sp3)‒H insertion18 as well as cyclopropanation reac-
tions (Supplementary Figure 4B).42 Notably, FAD domain de-
letion significantly destabilized the protein, as whole-cell alkyl-
ation assays performed with a protein denaturant pre-treatment 
revealed up to 33% lower activity of P411-CIS Q674* com-
pared to P411-CIS (Supplementary Figure 4C).43,44 Thus, FAD 
domain deletion exerts a destabilizing effect, but contributes to 
higher P411 expression levels and carbene transfer activity. 
Mounting evidence suggests that native P450-BM3 adopts a ho-
modimeric quaternary structure in solution via FAD domain in-
teractions, and that the dimeric form is required for oxo-transfer 
activity.34,45–48 The data presented here suggest that for non-nat-
ural carbene-transfer reactions a different, possibly monomeric, 
catalyst structure may be suitable or even beneficial. Attempts 
to obtain crystal structures of the FAD-truncated P411-HF var-
iant have unfortunately not been successful. 
Next, we compared 1-methylindole alkylation activities of 
P411-CIS and P411-HF as purified proteins and with different 
reducing agents (Supplementary Figure 5). We found that puri-
fied P411-CIS catalyzes 1-methylindole alkylation with 165 
TTN with sodium dithionite as reductant, 135 TTN with 
NADPH as reductant, but only 8 TTN in the absence of reduct-
ant. To our surprise, P411-HF showed 1890 TTN with NADPH 
(corresponding to 94% yield), 1750 TTN with sodium dithio-
nite, and an almost equally high 1670 TTN without any reduct-
ant present. Thus, P411-HF maintains a catalytically competent  
 
Figure 2: Characterization of P411-HF. (A) Comparison of 
P411-CIS and P411-HF in analytical (400 µL) biocatalytic whole-
cell reactions for formation of 3a under aerobic or anaerobic con-
ditions and different substrate and catalyst loadings. (B,C) Kinetics 
of whole cell-reactions for formation of 3a under anaerobic (B) and 
aerobic (C) conditions. Reactions were run with cells at OD600=30 
with 30 mM 1 and 45 mM 2 (anaerobic, B), or 10 mM 1 and 15 
mM 2 (aerobic, C). Initial turnover frequencies were calculated 
from samples analyzed 10 minutes after starting the reaction. Data 
in (A) to (C) were obtained from two to three independent assays 
with two replicates per variant. 
 
state of the heme cofactor even in the absence of reductant, in 
stark contrast to P411-CIS. While native P450 oxo-transfer 
chemistry requires a stoichiometric supply of electrons, P411 
carbene transfer catalysis functions without an electron supply 
as long as the iron cofactor is in the ferrous state.14 Therefore, 
truncating the reductase domain can be expected to be less con-
sequential for carbene transfer catalysis. The extent to which 
FAD domain truncation contributes to maintaining the enzyme 
in the catalytically active ferrous state remains to be deter-
mined. 
Lastly, we tested the substrate scope of P411-HF and its suita-
bility for synthesis of alkylated indoles. With 1-methylindole, 
preparative-scale reactions (0.6 mmol) delivered 3a with 83 % 
isolated yield (108 mg) (Figure 3). To our delight, we found that 
P411-HF selectively alkylates unprotected indoles at the C3 po-
sition. No N‒H insertion products were observed, and alkylated 
products were isolated in good yields across a range of substi-
tuted, unprotected indoles (Figure 3). We observed a clear reac-
tivity trend, with only trace amount of alkylation product ob-
tained for C4-substituted indoles, comparatively low yields for 
C5-substituted indoles, and good yields for indoles with substi-
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 tutions at C6 or C7. Presumably, substitutions at C4 or C5 inter-
fere with productive indole binding in the active site. Also, only 
low activity was observed for 1,2-dimethylindole; alkylation of 
this substrate was improved by the M263A mutation, which 
likely creates more space in the active site above the heme co-
factor and enables productive binding of this sterically hindered 
1,2-disubstituted indole. 
 
Figure 3: P411-HF indole alkylation substrate scope. Prepara-
tive-scale reactions were performed at 0.6 mmol scale (1-methyl-
indole) or 0.3 mmol scale (all other substrates) to yield the C3-al-
kylated products. Isolated yields are given; TTN are based on the 
isolated yield. aFor 1,2-dimethylindole, reactions were performed 
with variant P411-HF M263A and HPLC yield and TTN are given. 
 
Utilizing P411-HF as a starting point for additional cyclic 
alkene functionalization reactions 
While evolving for new functions, enzymes may gain activities 
for additional reactions that were not actively selected for. 
However, such promiscuous activities may in turn serve as evo-
lutionary starting points to evolve novel functions. 49–51 For ex-
ample, we found that variant P411-CIS, previously evolved 
from P450-BM3 for styrene cyclopropanation,14,15 showed 
more than 30-fold higher activity for 1-methylindole alkylation 
than P450-BM3 (Supplementary Table 1). Thus, P411-CIS was 
chosen as starting point for evolving indole alkylation activity, 
ultimately yielding variant P411-HF (Figure 4A). In turn, we 
speculated that P411-HF, engineered to accommodate a hetero-
cyclic structure near the catalytic iron center, may provide a 
good starting point for further evolution to unlock additional 
carbene transfer reactions to (hetero)cyclic alkenes. To test this 
hypothesis, we performed three evolutionary “case studies”, fo-
cusing on regioselective pyrrole alkylation, enantioselective in-
dole alkylation with an α-disubstituted carbene precursor, and 
cyclic alkene cyclopropanation. 
First, we attempted functionalizing pyrroles at either the C2 or 
C3 position, a considerable challenge for small-molecule cata-
lysts.27 Transition metal catalysis typically relies on electronic 
bias between the two positions and predominantly leads to func-
tionalization of C2‒H bonds.52 Alternatively, bulky substituents 
on the nitrogen were shown to shift regioselectivity towards the 
C3 position.
53 Enzyme catalysis can take advantage of precise 
substrate orientation within the active site, and thus potentially 
drive site selectivity independent of electronic or steric bias.54 
Accordingly, we speculated that the P411-HF active site could 
be tuned by directed evolution to favor alkylation at either the 
C2 or C3 position. 
We found that P411-HF catalyzes carbene transfer to 1-
methylpyrrole with 180 TTN, showing a 3:1 selectivity for the 
electronically favored C2-alkylated product (Figure 4A, Supple-
mentary Figure 6, Supplementary Table 3). Subsequent site-sat-
uration mutagenesis and screening revealed a new variant with 
mutation M263T, providing a 1:1 ratio of both products and 
confirming that active site mutations can indeed shift the selec-
tivity. Further evolution yielded two divergent P411 lineages 
that selectively yield the C2 or C3 alkylation products: variant 
P411-HF M263T G181E A82T makes the C3-alkylated product 
with 705 TTN and 9:91 C2:C3 ratio, whereas variant P411-HF 
M263T T87W G181K yields the C2-alkylated product with 485 
TTN and 98:2 C2:C3 ratio (Figure 4A). Thus, the P411-HF ac-
tive site can be sculpted with only three rounds of mutagenesis 
and screening to exert precise control over pyrrole heterocycle 
alkylation regioselectivity. The resulting variants may provide 
starting points for evolving enzymes to selectively alkylate 
other pyrrole derivatives. 
Next, we asked whether P411-HF could serve as a starting point 
to evolve for enantioselective indole alkylation using an α-di-
substituted carbene precursor (e.g., ethyl-2-diazopropanoate, 
Me-EDA), thereby delivering chiral alkylated indole core 5 
found in bioactive natural products.56 Alkylation of 1-methylin-
dole with Me-EDA represented a difficult biocatalytic reaction: 
no activity was found for either free hemin or for P411-CIS, and 
variant P411-HF M263Y delivered the product with only 2 
TTN. This low activity, however, was sufficient for GC-MS 
based screening, and we evolved this variant over seven rounds 
of site-saturation mutagenesis and screening to obtain variant 
P411-HF T87A Y263E A328Y L437M A268G T327P, which 
delivers 5 with 775 TTN (Figure 4B, Supplementary Figure 7, 
Supplementary Table 4). While this represents a >300-fold in-
crease in catalytic activity, enantioselectivity remained at ca. 
50% over the course of evolution. The limited enantioselectiv-
ity may be grounded in the enzymatic reaction mechanism: nu-
cleophilic attack by the indole C3 carbon at the iron-carbene 
center followed by protonation is generally considered the 
mechanistic pathway of indole alkylation.36,38,57 This process 
would require the enzyme to have perfect stereocontrol over the 
protonation step in order to yield high enantioselectivity. We 
speculate that further engineering of the P411-HF active site 
could possibly fine-tune hydrogen- bonding networks between 
the reaction intermediate and the protein, which might allow 
better control of the protonation step and lead to higher stere-
oselectivity. The evolved catalyst is nonetheless among the few 
P411’s efficiently catalyzing transfer of an α-disubstituted car-
bene. 
Finally, we reasoned that P411-HF may provide a good starting 
point to unlock cyclopropanation reactions of (hetero)cyclic in-
ternal alkenes. We first tested cyclopropanation using indene 
and EDA and found that P411-HF yielded the cis-configured 
cyclopropane 6a with 1880 TTN, 95:5 dr and 94% ee (Figure 
4C). This was significantly higher than P411-CIS, showing 305 
TTN, 69:31 dr and 78% ee (Supplementary Figure 8, Supple-
mentary Table 5), supporting the hypothesis that evolution for 
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Figure 4: Evolving P411-HF for selective (hetero)cycle functionalization reactions. Top: Schematic representation of the relation be-
tween protein sequence and catalytic function. A given enzyme sequence may exhibit additional ‘promiscuous’ functions that can be opti-
mized by directed evolution.55 We set out to test whether promiscuous activities of P411-HF, gained during evolution for 1-methylindole 
alkylation, could serve as starting points to evolve further (hetero)cycle functionalization reactions. (A) Evolution of P411-HF for regiose-
lective 1-methylpyrrole alkylation. (B) Evolution of P411-HF for enantioselective 1-methylindole alkylation with ethyl-2-diazopropanoate. 
(C) Evolution of P411-HF for stereoselective cyclic alkene cyclopropanation. Data in (A) to (C) were derived from two independent exper-
iments performed in duplicate; see Supplementary Tables 3 to 6 and Supplementary Figures 6 to 8 for evolutionary lineages and experimental 
details. 
 
indole alkylation in parallel raised activity for cyclopropanation 
of sterically similar substrates. One additional round of site-sat-
uration mutagenesis and screening delivered P411-HF M263Y, 
providing 6a with almost 4000 TTN, 97:3 dr and 96% ee (Fig-
ure 4C). Comparable hemoprotein cyclopropanation activity on 
internal alkene substrates was achieved previously only with 
iridium porphyrin-substituted hemoprotein variants,58 and this 
enzymatic reaction delivers a potentially useful cyclopropane 
core recently explored as pharmacophore.59 
Similar results were obtained on a less-activated cyclic alkene, 
1,3-cyclohexadiene (Figure 4C, Supplementary Figure 8, Sup-
plementary Table 6). Again, P411-HF showed enhanced cyclo-
propanation activity over its parent P411-CIS, and two addi-
tional rounds of site-saturation mutagenesis and screening 
yielded P411-HF M263W G181L, delivering the cis-configured 
cyclopropane 6b with 100 TTN, 91:1 dr and 73% ee. Lower 
TTNs (< 100) were observed on heterocyclic substrates, includ-
ing 2,3-benzofuran, 2,3-dihydrofuran and benzothiophene, 
while no activity was observed with aliphatic internal alkenes 
2,4-hexadiene, 2-octene, cyclopentene, cyclohexene or cyclo-
heptene, indicating that these substrates still present a challenge 
for the current P411-HF carbene transferase lineage. Nonethe-
less, the results presented here demonstrate that enzymes con-
taining the native iron-heme cofactor are capable of internal al-
kene cyclopropanation, with activity and selectivity tunable by 
directed evolution. 
 
Concluding Remarks 
Enzyme catalysis represents a potentially sustainable alterna-
tive to chemical synthesis. Unlocking its promise, however, re-
quires that enzymes perform equal or better than state-of-the-
art synthetic methods. In this study, we engineered a set of cy-
tochrome P411 variants for carbene transfer to heterocycles and 
internal alkenes, synthetically important substrate classes 
largely absent from the repertoire of carbene transferases de-
scribed to date. We tackled this problem with a two-tiered en-
gineering strategy, first subjecting a cytochrome P411 variant 
to a comprehensive directed evolution effort, which delivered 
the highly active indole C3-alkylation variant P411-HF. Further 
engineering of P411-HF towards more challenging heterocycle 
and internal alkene functionalizations then delivered a suite of 
P411 variants for a diverse set of heterocycle functionalization 
Page 5 of 9
ACS Paragon Plus Environment
Journal of the American Chemical Society
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 reactions. Only a few rounds of site-saturation mutagenesis and 
screening were required to achieve regioselective pyrrole alkyl-
ation, enantioselective indole alkylation, and stereoselective cy-
clic alkene cyclopropanation. The evolved enzymes catalyze 
hundreds to thousands of turnovers, are fully genetically en-
coded, and function with an earth-abundant iron cofactor. These 
variants complement existing transition metal catalysts for se-
lective heterocycle functionalizations, provide potential starting 
points for future directed evolution endeavors, and expand the 
catalytic repertoire of the carbene transferase family of en-
zymes. 
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